Clinical Application Evaluation of Salvia Miltiorrhiza Depside Salts for Injection
HAN Sheng1, ZHAO Xi-zi1, SHI Lu-wen1*, LIN Li-kai2, LI Da-kui3, CHEN Kai-xian4, XUAN Li-jiang4, MA Chuan-jiang5, MA Hai-ying6, FANG Wei-yi7, WANG Li-xia8, WEN Ai-dong9, FU Xiu-juan10, ZUO Yan11, LIU Xiao-ling12, LIU Xiang-hong13, LIU Guo-qiang14, ZHU Zhu3, CHEN Wan-sheng15, CHEN Wei-hong16, WU Fang-jian17, WU Yu-bo18, WU Hui19, ZHANG Wei20, ZHANG Bi-kui21, LIN Hui22, ZHOU Guo-hua23, OUYANG Rong24, HU Yuan-hui8, JIANG Ming-yan25, ZHAO Chun-jing26, JIA Le-chuan27, JIN Yue-ping28, TANG Hong-mei29, CAO Jun-ling30, LIANG Chun15, SHANG Hong-cai31, DONG Zhan-jun32, DONG Yu-gang33, ZHAI Suo-di34
1. Peking University International Research Center for Medical Administration, Beijing 100191, China; 2. Wuhan University Central South Hospital, Wuhan University Hospital Management Institute, Wuhan 430071, China; 3. Peking Union Medical College Hospital, Beijing 100730, China; 4. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; 5. Shandong Traditional Chinese Medicine University Hospital, Jinan 250014, China; 6. The Fourth Affiliated Hospital of China Medical University, Shenyang 110000, China; 7. East China Hospital Affiliated to Fudan University, Shanghai 200030, China; 8. Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China; 9. PLA Air Force Military Surgeon The First Affiliated Hospital of University, Xi'an 710032, China; 10. The Second Hospital of Jilin University, Changchun 130041, China; 11. Shaanxi Provincial People's Hospital, Xi'an 710068, China; 12. Inner Mongolia Autonomous Region People's Hospital, Hohhot 010017, China; 13. Shandong Qilu Hospital of Shandong University, Jinan 250012, China; 14. The Third Hospital of Hebei Medical University, Shijiazhuang 050051, China; 15. The Second Affiliated Hospital of Naval Military Medical University, Shanghai 200003, China; 16. Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences), Taiyuan 030032, China; 17. Yangtze River Shipping General Hospital, Wuhan 430015, China; 18. The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China; 19. The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China; 20. Henan Provincial People's Hospital, Zhengzhou 450003, China; 21. The Second Xiangya Hospital of Central South University, Changsha 410011, China; 22. Hainan Province Pharmaceutical Association, Haikou 570102, China; 23. Jinling Hospital Affiliated to Nanjing University School of Medicine, Nanjing 210000, China; 24. The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha 410007, China; 25. The First Affiliated Hospital of China Medical University, Shenyang 110001, China; 26. Chongqing Medical University The Second Affiliated Hospital of University, Chongqing 400010, China; 27. The General Hospital of Ningxia Medical University, Yinchuan 750004, China; 28. The First Hospital of Shanxi Medical University, Taiyuan 030001, China; 29. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China; 30. Beijing Zhong Eastern Hospital of Medical University, Beijing 100078, China; 31. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100007, China; 32. Hebei Provincial People's Hospital, Shijiazhuang 050051, China; 33. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China; 34. Peking University Third Hospital, Beijing 100191, China
Abstract：OBJECTIVE To take Salvia Miltiorrhiza depside salts for injection as an example, to explore the comprehensive clinical application evaluation method of traditional Chinese medicine injection, and to provide reference for the development and improvement of related work in the future. METHODS Through literature search and obtaining relevant literature information, systematically evaluate Salvia Miltiorrhiza depside salts for injection from the aspects of effectiveness, safety, pharmacoeconomics,compliance and label information. RESULTS In addition to the indications in the instructions, Danshen polyphenolate has considerable amount of high-quality clinical research evidence in cardiovascular disease, cerebrovascular disease and other over-indication indications.The literature evidence is also abundant in terms of safety and pharmacoeconomics. CONCLUSION The Salvia Miltiorrhiza depside salts for injection has plentiful and systematic clinical research evidence in terms of effectiveness, safety and pharmacoeconomics.However, as a large variety drug of clinical applications, itstill needs to make more research efforts in some aspects.
WANG Y P, XUAN L J. Demonstrative achievement of modernization of traditional Chinese medicine——research and development of Salvia Miltiorrhiza Polyphenolate and Salvia Miltiorrhiza Polyphenolate for Injection[J]. Bull Chin Acade Sci(中国科学院院刊), 2005,(5):31-34.
[2]
ZHANG J H, SUN X. Evidence-based Chinese Medicine(循证中医药学)[M]. Shanghai: Shanghai Science and Technology Press, 2018:184-186.
[3]
SHI L W, ZHU W T, WU J, et al. Technical Handbook of Pharmacoeconomic Evaluation of Chinese Patent Medicine(中成药药物经济学评价技术手册)[M]. Beijing: Peking Union Medical College Press, 2019: Preface.
[4]
YAN Y, YANG Y H, WANG W W, et al. Post-marketing safety surveillance of the Salvia Miltiorrhiza Depside Salt for Infusion: a real world study[J]. PLoS One, 2017, 12 (1):e0170182.
[5]
CAO X F, KONG F F. Analysis of 36 cases of adverse reactions of Salvia Miltiorrhiza Polyphenolate for Injection[J]. J Clin Ratio Use(临床合理用药杂志), 2018, 11(1):129-130.
[6]
YU Y X, WANG C, LIU G H. Summary of the literature on adverse reactions of Salvia Miltiorrhiza Polyphenolate for Injection[J]. Chin J Drug Abuse Prev Treat(中国药物滥用防治杂志), 2017, 23(2):115+118.
[7]
LIAO X J, YAN M, DENG Y H, et al. A case of adverse reaction caused by injection of Salvia Miltiorrhiza Polyphenolate[J]. China Pharm(中国药师), 2016, 19(6):1142-1143.
[8]
ZHU Y X, SUN X Z, LI C H. 2 Cases of adverse reaction of Salvia Miltiorrhiza Polyphenolate for Injection[J]. J North Pharm (北方药学), 2015, 12(10):112-113.
[9]
ZHAO C, WANG Q. Salvia Miltiorrhiza Polyphenolate for Injection in the treatment of chest paralysis[J]. Jilin Tradit Chin Med(吉林中医药), 2010, 30(7):615.
[10]
DOU F, QIAO Y, HU D M, et al. A case of high fever and chills caused by Injection of Salvia Miltiorrhiza Polyphenolate in coronary heart disease[J]. China Pharm(中国药师), 2018, 21(3):466-467.
[11]
TIAN L L, ZHOU T R, WU J, et al. A case of adverse reaction caused by Injection of Salvia Miltiorrhiza Polyphenolate[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2015, 24(9):566-567.
[12]
LI H. A case of skin rash caused by Injection of Salvia Miltiorrhiza Polyphenolate[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2011, 20(1):41.
[13]
KONG F F, SHEN J, GUO L J, et al. A case of skin allergy caused by unreasonable application of Salvia Miltiorrhiza Polyphenolate for Injection[J]. China Med(中国医药), 2014, 9(9):1392-1392.
[14]
YAN J Q. Observing the clinical efficacy and safety of Salvia Miltiorrhiza Polyphenolate Injection in the treatment of coronary heart disease[J]. Guide Health Care(养生保健指南), 2019, (9):67.
[15]
CAO H Y, ZHOU H. Observation of the clinical efficacy and safety of Salvia Miltiorrhiza Polyphenolate Injection in the treatment of coronary heart disease[J]. World Latest Med Inf(世界最新医学信息文摘), 2019, 19(77):174-175.
[16]
GUAN Y, LIU B, LIAO X J. A systematic review of the effectiveness and safety of Salvia Miltiorrhiza Polyphenolate in the treatment of unstable angina pectoris[J]. Guide China Med(中国医药指南), 2013, 11(19):50-52.
[17]
TAO J. The clinical efficacy and safety of Salvia Miltiorrhiza Polyphenolate in the treatment of coronary heart disease[J]. Diet & Health Care(饮食保健), 2019, 6(1):88.
[18]
GUO Y, TIAN J W, XUE Q, et al. The clinical efficacy and safety of Salvia Miltiorrhiza Polyphenolate in the treatment of coronary heart disease[J]. Health Vision(健康大视野), 2018, (10):40.
[19]
TIAN L, ZHOU L, YU W M, et al. Clinical efficacy and safety of Salvia Miltiorrhiza Polyphenolate in the treatment of coronary heart disease[J]. Home Med Med(家庭医药), 2017, (10):75-76.
[20]
HE X, LU S W, GUO J Y. The clinical efficacy and safety of Salvia Miltiorrhiza Polyphenolate in the treatment of coronary heart disease[J]. Chin J Clin Pharmacol(中国临床药理学杂志), 2016, 32(2):105-107.
[21]
WANG C H. Efficacy and safety analysis of Salvia Miltiorrhiza Polyphenolate in patients with coronary heart disease[J]. China Mod Med Appl(中国现代药物应用), 2019, 13(10):85-86.
[22]
GUO H F. Efficacy and safety analysis of Salvia Miltiorrhiza Polyphenolate (for Injection) in the treatment of elderly patients with coronary heart disease and angina pectoris[J]. Elec J Clin Med Liter(临床医药文献电子杂志), 2018, 5(93):36-37.
[23]
WANG Y P, XUAN L J. Research and development of Salvia Miltiorrhiza Polyphenolate and Salvia Miltiorrhiza Polyphenolate for Injection, a model achievement of the modernization of traditional Chinese medicine[J]. Bull Chin Acade Sci(中国科学院院刊), 2005(5):31-34.
[24]
MIAO Y, GAO Z Y, XU F Q, et al. Clinical study of Salvia Miltiorrhiza Polyphenolate in the treatment of coronary heart disease angina pectoris (heart blood stasis syndrome)[J]. Chin New Drugs Clin Pharm(中药新药与临床药理), 2006(2):140-144 .
[25]
CHEN X L. Efficacy analysis of Salvia Miltiorrhiza Polyphenolate Combined with Trimetazidine Capsules in the treatment of angina pectoris of coronary heart disease[J]. Mod Pract Med(现代实用医学), 2018, 30(10):1368-1370.
[26]
XIAO P U, MA C, WANG W W, et al. Efficacy and safety of Salvia Miltiorrhiza Polyphenolate for Injection in the treatment of coronary heart disease and angina pectoris (heart blood stasis syndrome)[J]. Cardiovascular Dis J Integrated Tradit Chin West Med(Ed)(中西医结合心血管病电子杂志), 2016, 4 (23):133,135.
[27]
SHEN W, OU Y, SUN S J, et al. Single-center, randomized controlled trial of Salvia Miltiorrhiza Polyphenolate in the treatment of PCI-related myocardial injury during perioperative coronary intervention [J]. Chin J Integr Tradit Chin West Med(中国中西医结合杂志), 2019, 39(4):412-417.
[28]
LIN Y C, YU Z S. The effect of Salvia Miltiorrhiza Polyphenolate adjuvant therapy on the levels of platelet membrane glycoprotein CD62p and CD63 in patients with acute coronary syndrome and the observation of the therapeutic effect[J]. China Pharm(中国药师), 2016, 19(12):2335-2336,2338.
[29]
SHI Q, CHENG K, TIAN J Y.Effects of Salvia Miltiorrhiza Polyphenolate Combined with clopidogrel on cardiac function, endothelial function and inflammatory factors in patients with acute coronary syndrome[J]. Cardiovascular Dis J Int(中西医结合心血管病杂志), 2017, 15 (23):3026-3029.
[30]
WANG Y. Analysis of the efficacy of Salvia Miltiorrhiza Polyphenols in patients with acute myocardial infarction[J]. Chin J Hemor(中国血液流变学杂志), 2012, 22(4):590-591.
[31]
CUI H, LI X Y, GAO X W, et al. A prospective randomized multicenter controlled trial on salvianolate for treatment of unstable angina pectoris in a Chinese elderly population[J]. Chin J Integ Med(中国结合医学杂志), 2019, 25(10):728-735.
[32]
XUE L, OU S L, BAO H G, et al. Efficacy observation of Salvia Miltiorrhiza Polyphenolate in the treatment of unstable angina pectoris[J]. Chin J Evid Base Cardiovascular Med(中国循证心血管医学杂志), 2017, 9(7):851-853.
[33]
LI X G, ZHAO J. Effects of Salvia Miltiorrhiza Polyphenolate Combined with western medicine on cardiac function and inflammatory factor levels in patients with chronic heart failure[J]. Clin Res Pract(临床医学研究与实践), 2018, 3(2):7-8,11.
[34]
SHANG J, QU L G, GE L J. Efficacy of creatine phosphate combined with Salvia Miltiorrhiza Polyphenolate in the treatment of coronary heart disease and heart failure[J]. J North Pharm(北方药学), 2014, 11(12):74-75.
[35]
LIN N B, ZHENG W H, LIN Y H. Efficacy of creatine phosphate sodium combined with Salvia Miltiorrhiza Polyphenolate in the treatment of coronary heart disease and heart failure[J]. Strait Pharm J(海峡药学), 2017, 29(12):189-190.
[36]
WU S X. The clinical efficacy of Salvia Miltiorrhiza Polyphenolate Combined with edaravone in the treatment of acute ischemic stroke[J]. Orien Food Ther Health Care(东方食疗与保健), 2017(3).
[37]
LIN Y, PENG H F. The clinical efficacy of injection salvia polyphenolate in the treatment of acute cerebral infarction[J]. Chin J Clin Ration Drug Use(临床合理用药杂志), 2018, 11(36):51-53.
[38]
ZHAO L Y, LONG H X, ZHAO J, et al. Efficacy of Salvia Miltiorrhiza Polyphenolate Combined with butylphthalide in the treatment of acute cerebral infarction and its influence on hemorheology[J]. Cardiovascular Dis J Int(中西医结合心脑血管病杂志), 2018, 16(18): 2757-2759.
[39]
PAN Y X, CHEN J, ZHONG S S, et al. A comparative study of Salvia Miltiorrhiza Polyphenolate Combined with aspirin in the treatment of acute cerebral infarction[J]. J Clin Psychosomatic Dis(临床心身疾病杂志), 2016, 22(1): 13-14.
[40]
LUO X D, YANG K J, H Z W, et al. Efficacy of Salvia Miltiorrhiza Polyphenolate Combined with conventional treatment of acute cerebral infarction and its effect on serum interleukin-6[J]. China Pharm(中国药师), 2017, 20(8):1403-1405.
[41]
CHEN J, ZHOU H Z, WANG Y L, et al. Effects of Salvia Miltiorrhiza Polyphenolate Combined with losartan potassium on related factors of elderly diabetic nephropathy[J]. West Med (西部医学), 2018, 30(10):1451-1455,1461.
[42]
ZHANAG W S. Clinical efficacy of atorvastatin combined with Salvia Miltiorrhiza Polyphenols in the treatment of chronic obstructive pulmonary with pulmonary hypertension[J]. Inner Mongo Med J(内蒙古医学杂志), 2019, 51(4):439-440.
[43]
JIANG X Y. Clinical study of Salvia Miltiorrhiza Polyphenolate Injection in the treatment of ischemic colitis[J]. Chin Med Sci(中国医药科学), 2018, 8(24):42-44.
[44]
LIU J L, GUO Y J, MENG F S, et al. Clinical efficacy of Salvia Miltiorrhiza Polyphenolate Combined with low molecular weight heparin calcium in the treatment of ICU patients with qi stagnation and blood stasis type deep vein thrombosis of lower extremities[J]. J Guangzhou Univ Tradit Chin Med(广州中医药大学学报), 2019, 36(2):192-196.
[45]
ZHAO Y, YANG C S, TIAN C. Clinical study of Salvia Miltiorrhiza Polyphenolate Combined with mouse nerve growth factor in the treatment of spinal cord injury[J]. China Pharm(中国药业), 2018, 27(22):62-65.
[46]
YANG W B. Minimum cost analysis of 3 kinds of Danshen compound preparations in the treatment of coronary heart disease and angina pectoris[J]. J China Pharm(中国药房), 2012, 23(38):3557-3559.
[47]
LI J, YANG Q, DONG J, et al. Clinical efficacy and cost-effectiveness analysis of three regimens in the treatment of coronary heart disease and angina pectoris[J]. Cardiovascular Dis J Int(中西医结合心脑血管病杂志), 2016, 14(22):2664-2666.
[48]
ZHANG Y F, QIN Z L, LIU J, et al. Pharmacoeconomics study of 4 kinds of Danshen preparations in the treatment of coronary heart disease and angina pectoris[J]. Chongqing Med J(重庆医学), 2016, 45(8):1081-1083.
[49]
SHI Y F, YAN H, SUN S G, et al. Systematic review and pharmacoeconomic analysis of two Danshen Chinese medicine injections in the treatment of coronary heart disease and angina pectoris[J]. Chin J Evid Base Med(中国循证医学杂志), 2014, 14(3):287-291.
[50]
DONG P X, FAN D, HAN S, et al. Evidence-based pharmacoeconomics study of Salvia Miltiorrhiza Polyphenolate for Injection in the treatment of unstable angina pectoris[J]. Drug Eval(药品评价), 2016, 13(20):18-21,30.
[51]
FENG S, HU M. Pharmaccoeconomic evaluation of Danshen Ligustrazine Injection vs Danshen Polyphenolate Injection in the treatment of coronary heart disease and angina pectoris[J]. J Pharm Pract(药学实践杂志), 2018, 36(2):147-155.
[52]
DONG P X, HU H, GUAN X D, et al. Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease[J]. Chin Med, 2018, 13:[2021-03-17]. https://11doi.org.10.11861513020-018-0185-x.
[53]
XIAO J, HU M. Clinical efficacy and pharmacoeconomic evaluation of Danshen ligustrazine injection compared with Danshen polyphenolate injection in the treatment of cerebral infarction[J]. Chin J Evid Base Cardiov Med(中国循证心血管医学杂志), 2016, 8(10):1171-1176.
[54]
LIU J. Cost-effectiveness analysis of traditional Chinese medicine injection in the treatment of acute cerebral infarction[J]. Tianjin Pharm(天津药学), 2016, 28(3):8-10.
[55]
ZHANG Z Q. Pharmaccoeconomic analysis of different Danshen preparations in the treatment of ischemic stroke[J]. China's Naturopathy(中国民间疗法), 2019, 27(9):43-44.
[56]
LI P J, ZHAO Y M. Analysis of the drug application of Salvia Miltiorrhiza and its active ingredients in our hospital from 2011 to 2013[J]. China Mod Med Appl(中国现代药物应用), 2014(11):178-181.
[57]
YANG L L, DUO D L, YAN Y J, et al. Analysis of the application of traditional Chinese medicine injections in our hospital from 2015 to 2017[J]. Chin J Clin Rational Drug Use(临床合理用药杂志), 2019(19):7-8.
2021, Vol. 56 
